Back to Journals » Patient Preference and Adherence » Volume 11

Medication nonadherence among South American patients with schizophrenia

Authors Caqueo-Urízar A, Urzúa A, Fond G, Boyer L

Received 27 June 2017

Accepted for publication 22 August 2017

Published 6 October 2017 Volume 2017:11 Pages 1737—1744

DOI https://doi.org/10.2147/PPA.S144961

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Johnny Chen

Alejandra Caqueo-Urízar,1 Alfonso Urzúa,2 Guillaume Fond,3,4 Laurent Boyer5

1Universidad de Tarapacá, Escuela de Psicología y Filosofía, Arica, Chile; 2Universidad Católica del Norte, Avda, Angamos, Antofagasta, Chile; 3Université Paris Est-Créteil, Pôle de Psychiatrie des Hôpitaux Universitaires H Mondor, INSERM U955, Eq Psychiatrie Translationnelle, DHU Pe-Psy, France; 4Fondation FondaMental Fondation de coopération scientifique en santé mentale, France; 5Aix-Marseille Univ, EA 3279 – Public Health, Chronic Diseases and Quality of Life – Research Unit, Marseille, France

Objective: The objective of this research was to quantify nonadherence to medication and explore the determinants of nonadherence in patients diagnosed with schizophrenia (SZ) from three countries in Latin America (Bolivia, Peru, and Chile).
Methods: This study was conducted in public mental health centers in Bolivia, Peru, and Chile. The data collected included drug attitude inventory (DAI-10), sociodemographic information, and clinical and treatment characteristics of patients with SZ. Multivariate analysis with multiple linear regression was then performed to identify variables that were potentially associated with the DAI score (dependent variable).
Results: Two hundred and fifty-three patients diagnosed with SZ participated in the study and 247 fully completed the DAI-10. In the multivariate analysis, medication nonadherence was associated with being a woman (β=-0.16, p=0.029), younger age (β=0.17, p=0.020), younger age at onset of disease (β=-0.17, p=0.019), and lower insight (β=-0.30, p<0.001).
Conclusion: Being a female, younger age, younger age at onset of disease, and lower insight were the main features associated with nonadherence. If future longitudinal studies confirm these findings, these factors should not be neglected in Latin American mental health public policies to address the problem of nonadherence.

Keywords: medication adherence, schizophrenia, gender, insight

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]